6.96

2.04% +0.10

Benitec Biopharma Inc (BNTC)

Overview News Price History Discussions Forecast Stock Split

Benitec Biopharma Inc stock is currently priced at $6.96, with a 24-hour trading volume of 22,836. It has seen a +2.04% increased in the last 24 hours and a +41.41% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $6.82 pivot point. If it approaches the $7.08 resistance level, significant changes may occur.

Previous Close:

$6.86

Open:

$6.96

24h Volume:

22,836

Market Cap:

$18.15M

Revenue:

$59,000

Net Income/Loss:

$-21.81M

P/E Ratio:

-0.4108

EPS:

-16.9418

Net Cash Flow:

$-18.07M

1W Performance:

+45.83%

1M Performance:

+41.41%

6M Performance:

+102.90%

1Y Performance:

+3,259%

1D Range:

$6.6601

$7.13

52W Range:

$0.1606

$7.42

Benitec Biopharma Inc Stock (BNTC) Company Profile

Name

Benitec Biopharma Inc

Sector

Healthcare (1203)

Industry

Biotechnology (685)

Phone

510 780 0819

Address

3940 Trust Way, Hayward, CA

Employee

Twitter

@BenitecLtd

Next Earnings Date

2024-05-13

Latest SEC Filings

BNTC's Discussions on Twitter

Benitec Biopharma Inc Stock (BNTC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-05-20	Downgrade	Ladenburg Thalmann	Buy → Neutral
Apr-20-20	Initiated	Ladenburg Thalmann	Buy
Feb-26-16	Downgrade	Maxim Group	Buy → Hold
Dec-31-15	Reiterated	Maxim Group	Buy
Sep-16-15	Reiterated	Maxim Group	Buy

Benitec Biopharma Inc Stock (BNTC) Latest News

Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study

GlobeNewswire Inc.

Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million

GlobeNewswire Inc.

Wall Street Breakfast: The Week Ahead

Seeking Alpha

Benitec Biopharma to Participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference

GlobeNewswire Inc.

Benitec Biopharma Inc Stock (BNTC) Financials Data

Benitec Biopharma Inc (BNTC) Revenue 2024

BNTC reported a revenue (TTM) of $59.00 thousand for the quarter ending June 30, 2021.

Benitec Biopharma Inc (BNTC) Net Income 2024

BNTC net income (TTM) was -$21.81 million for the quarter ending December 31, 2023, a -15.73% decrease year-over-year.

Benitec Biopharma Inc (BNTC) Cash Flow 2024

BNTC recorded a free cash flow (TTM) of -$18.07 million for the quarter ending December 31, 2023, a +0.55% increase year-over-year.

Benitec Biopharma Inc (BNTC) Earnings per Share 2024

BNTC earnings per share (TTM) was -$10.95 for the quarter ending December 31, 2023, a +61.79% growth year-over-year.

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.